Cargando…

Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia

PURPOSE: In this study, we examined the effects of dapagliflozin on changes in hematopoiesis, iron metabolism, and body composition indices in elderly type 2 diabetic patients with renal impairment and investigated the potential of dapagliflozin to treat renal anemia. PATIENTS AND METHODS: The parti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osonoi, Takeshi, Shirabe, Shinichiro, Saito, Miyoko, Hosoya, Mitsuru, Watahiki, Norie, Douguchi, Satako, Ofuchi, Kensuke, Katoh, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290476/ https://www.ncbi.nlm.nih.gov/pubmed/37363130 http://dx.doi.org/10.2147/DMSO.S411504

Ejemplares similares

Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study
por: Osonoi, Takeshi, et al.
Publicado: (2023)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
por: Osonoi, Takeshi, et al.
Publicado: (2020)

Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study
por: Osonoi, Takeshi, et al.
Publicado: (2019)

Four‐year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes
por: Kobori, Mariko, et al.
Publicado: (2016)

S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy
por: Kondo, Shinnosuke, et al.
Publicado: (2021)

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial
por: Koshino, Akihiko, et al.
Publicado: (2023)

Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron
por: Silverberg, Donald S, et al.
Publicado: (2014)

Effects of Exogenous Transferrin on the Regulation of Iron Metabolism and Erythropoiesis in Iron Deficiency With or Without Anemia
por: Li, Yihang, et al.
Publicado: (2022)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Iron Mining for Erythropoiesis
por: Correnti, Margherita, et al.
Publicado: (2022)

Efficacy of ipragliflozin as monotherapy or as add‐on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics
por: Osonoi, Takeshi, et al.
Publicado: (2017)

Iron deficient erythropoiesis might play key role in development of anemia in cancer patients
por: Park, Silvia, et al.
Publicado: (2015)

The Interplay between Drivers of Erythropoiesis and Iron Homeostasis in Rare Hereditary Anemias: Tipping the Balance
por: Grootendorst, Simon, et al.
Publicado: (2021)

Zebrafish erythropoiesis and the utility of fish as models of anemia
por: Kulkeaw, Kasem, et al.
Publicado: (2012)

P1567: ALK2 INHIBITION LOWERED HEPCIDIN AND LIBERATED SPLEEN IRON FOR ERYTHROPOIESIS IN ANEMIA OF INFLAMMATION
por: Wang, C.-Y., et al.
Publicado: (2022)

Erythropoiesis and iron metabolism in Hodgkin's disease.
por: Al-Ismail, S., et al.
Publicado: (1979)

Erythropoiesis and Iron Sulfur Cluster Biogenesis
por: Ye, Hong, et al.
Publicado: (2010)

Crosstalk between Erythropoiesis and Iron Metabolism
por: Rivella, Stefano, et al.
Publicado: (2010)

Crosstalk between Iron Metabolism and Erythropoiesis
por: Li, Huihui, et al.
Publicado: (2010)

Effect of Hemodialysis on Plasma Glucose Profile and Plasma Level of Liraglutide in Patients with Type 2 Diabetes Mellitus and End-Stage Renal Disease: A Pilot Study
por: Osonoi, Takeshi, et al.
Publicado: (2014)

Chk1 Haploinsufficiency Results in Anemia and Defective Erythropoiesis
por: Boles, Nathan C., et al.
Publicado: (2010)

Relationships between lifestyle patterns and cardio-renal-metabolic parameters in patients with type 2 diabetes mellitus: A cross-sectional study
por: Ogihara, Takeshi, et al.
Publicado: (2017)

Breakfast skipping is associated with persistently increased arterial stiffness in patients with type 2 diabetes
por: Mita, Tomoya, et al.
Publicado: (2020)

Iron Loading and Overloading due to Ineffective Erythropoiesis
por: Tanno, Toshihiko, et al.
Publicado: (2010)

The relationship between systemic iron homeostasis and erythropoiesis
por: Rishi, Gautam, et al.
Publicado: (2017)

Imbalance of erythropoiesis and iron metabolism in patients with thalassemia
por: Huang, Yumei, et al.
Publicado: (2019)

A critical role for mTORC1 in erythropoiesis and anemia
por: Knight, Zachary A, et al.
Publicado: (2014)

Lower intake of saturated fatty acids is associated with persistently higher arterial stiffness in patients with type 2 diabetes
por: Mita, Tomoya, et al.
Publicado: (2020)

Switching α-Glucosidase Inhibitors to Miglitol Reduced Glucose Fluctuations and Circulating Cardiovascular Disease Risk Factors in Type 2 Diabetic Japanese Patients
por: Hariya, Natsuyo, et al.
Publicado: (2014)

Biomarkers of Hypochromia: The Contemporary Assessment of Iron Status and Erythropoiesis
por: Urrechaga, Eloísa, et al.
Publicado: (2013)

A biomathematical model of human erythropoiesis and iron metabolism
por: Schirm, Sibylle, et al.
Publicado: (2020)

Normal and dysregulated crosstalk between iron metabolism and erythropoiesis
por: Ginzburg, Yelena, et al.
Publicado: (2023)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia
por: Pashos, Chris L., et al.
Publicado: (2011)

Defective erythropoiesis in bone marrow is a mechanism of anemia in children with cancer.
por: Kim, MunHee, et al.
Publicado: (2002)

Pro-Inflammatory Cytokine-Mediated Anemia: Regarding Molecular Mechanisms of Erythropoiesis
por: Morceau, F., et al.
Publicado: (2009)

Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia
por: ZHOU, SHUQIN, et al.
Publicado: (2014)

NFAT-mediated defects in erythropoiesis cause anemia in Il2(−/−) mice
por: Giampaolo, Sabrina, et al.
Publicado: (2017)

Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease
por: Maruyama, Takashi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_08uali7a9shnmo164v3pqp7j2q